Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Iparomlimab and Tuvonralimab Injection (QL1706)Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic Cancer

A legfontosabb adatok

Ki végzi
Tongji Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
37 fő, tervezett
Kezdés
2026. szept. 14.
Várható befejezés
2029. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Iparomlimab and Tuvonralimab Injection (QL1706)
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Aged between 18 and 75 years old, with no gender restriction
  • Have been fully informed of this study and voluntarily signed the informed consent form
  • Patients with histopathologically confirmed pancreatic ductal adenocarcinoma (PDAC) with locally advanced lesions, meeting any of the following criteria and having no distant metastasis:; ① Tumors located in the pancreatic head and neck:; Tumor encasement of the superior mesenteric artery (SMA) exceeding 180°; Tumor encasement of the celiac trunk exceeding 180°; Tumor invasion or embolization (tumor thrombus or blood thrombus) rendering the superior mesenteric vein or portal vein unresectable for reconstruction; Extensive tumor involvement of the distal jejunal draining branch of the superior mesenteric vein; Tumors located in the pancreatic body/tail:; <!-- -->; Tumor encasement of the superior mesenteric artery or celiac trunk exceeding 180°; Involvement of the celiac trunk and abdominal aorta; Tumor invasion or embolization (tumor thrombus or blood thrombus) making resection and reconstruction of the superior mesenteric vein or portal vein impossible
  • Good physical status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
  • Willing and able to comply with medical advice and receive combination therapy with gemcitabine for injection and paclitaxel (albumin-bound) for injection
  • No dysfunction of major organs, and laboratory test results meet the basic requirements for chemotherapy, as follows:; Absolute neutrophil count ≥ 1.5×10⁹/L; Platelet count ≥ 90×10⁹/L; Hemoglobin (Hb) ≥ 90 g/L; Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 times the upper limit of normal (ULN); for patients with liver metastasis, AST and ALT ≤ 5.0 times ULN; Total bilirubin ≤ 1.5 times ULN; Serum creatinine ≤ 1.5 times ULN; Q-T interval on electrocardiogram ≤ 450 ms; Normal serum electrolytes (sodium, potassium, chloride and total calcium)
  • Women of childbearing potential must agree to use contraceptive measures throughout the study period and for 3 months after study completion; they must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding. Male participants must agree to use contraceptive measures during the study and for 3 months after the end of the study
  • No other contraindications to treatment prior to enrollment. The patient voluntarily participates in the trial, has good treatment compliance, and can cooperate with trial observations

Ki nem vehet részt

  • Subjects who have previously received first-line treatment for pancreatic adenocarcinoma
  • Severe cardiovascular diseases occurring within 12 months prior to admission, including symptomatic coronary heart disease, grade ≥ II congestive heart failure, uncontrolled arrhythmia, or myocardial infarction
  • Presence of severe uncontrolled concurrent infection, other severe uncontrolled comorbidities, or moderate to severe renal impairment
  • Use of corticosteroids or other systemic immunosuppressive therapies within 14 days prior to admission
  • Subjects who received investigational drug treatment within 4 weeks before enrollment (participation in other clinical trials)
  • Use of immunosuppressive drugs within 4 weeks before the first dose of study treatment, excluding topical or physiologic doses of systemic corticosteroids (i.e., prednisone ≤ 10 mg/day or equivalent doses of other corticosteroids) administered via nasal spray, inhalation or other routes, or corticosteroids used for the prevention of contrast medium allergy
  • Receipt of live attenuated vaccines within 4 weeks before the first dose of study treatment or during the study period
  • History of other malignant tumors within the past 5 years (excluding basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the cervix, and breast cancer)
  • Complicated gastroduodenal obstruction/hemorrhage, digestive dysfunction, or malabsorption syndrome
  • History of allergic reactions to the study medications used in this trial
  • Active autoimmune diseases (including but not limited to uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilator therapy). Exceptions may be made for patients with hypothyroidism managed solely with hormone replacement therapy and patients with skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia)
  • Medical history of primary immunodeficiency
  • Known active pulmonary tuberculosis
  • History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation
  • Positive HIV antibody, or active hepatitis B or hepatitis C infection (Hepatitis B: positive HBsAg with HBV DNA ≥ 10⁴ copies/mL; Hepatitis C: positive HCV antibody and HCV-RNA requiring antiviral treatment)
  • Subjects with contraindications to treatment with gemcitabine for injection and/or albumin-bound paclitaxel for injection, or with known severe hypersensitivity to gemcitabine for injection and/or albumin-bound paclitaxel for injection
  • Other factors that, in the investigator's opinion, may compromise subject safety or trial compliance, such as severe diseases requiring comprehensive treatment (including psychiatric disorders), significant laboratory abnormalities, or other familial and social factors
  • Patients with acinic cell carcinoma, pancreatoblastoma, solid pseudopapillary neoplasm, or pancreatic neuroendocrine neoplasm
  • Pregnant or lactating women; women of childbearing potential with a positive baseline pregnancy test
  • Uncontrolled pleural effusion, pericardial effusion, or ascites

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to learn if the study drug QL1706 (iparomlimab and tuvonralimab injection) works to treat locally advanced pancreatic cancer in adults when it is given together with chemotherapy and Stereotactic radiotherapy. It will also learn about the safety of this combination treatment.

A teljes eredeti leírásKevesebb

Around 37 adults aged 18 to 75 who have pancreatic cancer that has grown into nearby tissue and cannot be removed by surgery, but has not spread to other parts of the body, and who have not yet received any treatment for it, will take part in this study.

The main questions it aims to answer are:

Does the combination of QL1706, chemotherapy and radiation make the tumor shrink or stop growing, making it suitable for surgery? How long do participants live without their cancer getting worse, and how long do they live overall? What medical problems do participants have when taking this combination treatment? All participants in this study will receive the same treatment. There is no placebo (a look-alike substance that contains no drug) and no comparison group. Researchers will compare the results of participants in this study with the results usually seen in people who receive chemotherapy alone, to see if adding QL1706 and radiation helps.

Participants will:

Receive QL1706 through a vein (by intravenous infusion) once every 3 weeks Receive 2 chemotherapy drugs through a vein on days 1 and 8 of every 3-week cycle, for 2 cycles. The 2 drugs are gemcitabine and nab-paclitaxel Then receive 5 doses of focused radiation therapy to the pancreas, given about every other day over about 2 weeks, together with 2 more cycles of QL1706 and chemotherapy. Participants whose cancer gets worse during treatment will stop this part of the study Have CT or MRI scans every 6 weeks so the researchers can see whether the cancer has shrunk Have blood tests, physical examinations and other checkups during treatment Be reviewed by a team of pancreatic cancer specialists to see if surgery to remove the tumor is possible. Participants who can have surgery will have the surgery and then 2 to 4 more cycles of QL1706 and chemotherapy. Participants who cannot have surgery, and whose cancer has not grown, will keep receiving QL1706 and chemotherapy until their cancer gets worse, the treatment becomes too hard to tolerate, or they are no longer able to take part Tell the study team about any medical problems they have, which will be recorded throughout the study.

A vizsgálat csoportja

  • QL1706 combined with AG and SBRTA vizsgált kezelés

    Receive QL1706 through a vein (by intravenous infusion) once every 3 weeks Receive 2 chemotherapy drugs through a vein on days 1 and 8 of every 3-week cycle, for 2 cycles. The 2 drugs are gemcitabine and nab-paclitaxel Then receive SBRT to the pancreatic cancer, given about every other day over about 2 weeks, together with 2 more cycles of QL1706 and chemotherapy.

    Kezelés: Iparomlimab and Tuvonralimab Injection (QL1706)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Clinical Study of Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic Cancer
A regiszteradat frissítve
2026. november 16.